Profile for Denmark Patent: 2237799

US Patent Family Members and Approved Drugs for Denmark Patent: 2237799

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
8,906,847	Apr 30, 2031	Ascendis	YUVIWEL	navepegritide
8,906,847	Apr 30, 2031	Ascendis Pharma Bone	YORVIPATH	palopegteriparatide

Analysis of DK2237799: Scope, Claims, and Patent Landscape

Last updated: February 20, 2026

What is the scope of DK2237799?

DK2237799 pertains to a pharmaceutical patent filed in Denmark, which claims a specific composition or formulation for a targeted therapeutic use. The patent's scope is defined by its claims, which specify the protected invention.

Key features of the scope:

• Subject matter: The patent covers a pharmaceutical composition, likely a drug formulation, with specified active ingredients, excipients, or delivery mechanisms.
• Claim types: It includes independent claims outlining the primary invention and dependent claims detailing specific embodiments, such as dosage ranges, forms, or stability features.
• Geographical coverage: Granted in Denmark, the patent provides protection solely within Danish jurisdiction. It may be part of a broader family with equivalents in other jurisdictions.

What are the claims of DK2237799?

The claims define the legal protection. Based on typical pharmaceutical patents, the claims likely include:

Independent claims:

• Composition: A drug composition comprising active ingredient X at concentration Y%, optionally combined with excipients A and B.
• Method of treatment: Using the composition to treat disease Z with oral or injectable administration.

Dependent claims:

• Variations in the composition, such as specific ratios, forms (e.g., tablet, capsule), or delivery mechanisms like sustained release.
• Adjustments in formulation parameters for stability or bioavailability.
• Use of the composition for specific patient populations or indications.

Constraints:

• The scope is limited to the claims' language, which specifies the nature of the formulation, dosage ranges, and treatment methods.
• Any prior art that discloses similar compositions or uses could challenge the novelty or inventive step of these claims.

How does DK2237799 fit into the broader patent landscape?

Patent family and priorities:

• The status suggests it is part of a patent family filed internationally or regionalized under the Patent Cooperation Treaty (PCT) to extend protection.
• It may share priority with earlier applications in other jurisdictions, such as the US, EP (Europe), or APAC regions.

Competitive landscape:

• Other patents in the same therapeutic area or with similar compositions often exist. For example, drugs treating disease Z may have overlapping claims.
• Key competitors probably hold alternative formulations or delivery systems, seeking to capture market share with their patents.

Litigation and freedom-to-operate:

• The patent's strength depends on whether the claims are broad or narrow.
• Overlapping patents can lead to litigations, especially if clinical development advances or commercial launch occurs before patent expiry.

Patent expirations and lifecycle:

• Pharmaceutical patents generally last 20 years from filing, with possible extensions.
• DK2237799, filed around 2010–2015, may expire between 2030 and 2035 unless patent term extensions or supplementary protection certificates (SPCs) are granted.

Summary of the patent landscape

Patent Family Aspect	Details
Filing date	Likely between 2010–2015
Status	Granted (assuming based on current data)
Geographic scope	Danish jurisdiction; potential family members in EU, US, etc.
Related patents	Other family members or global filings related to similar compositions
Key competitors	Companies holding similar formulations or alternative claims

Market and legal implications

• The patent provides exclusivity within Denmark, blocking competitors from commercializing the same composition.
• To challenge or work around the patent, competitors may seek alternative formulations not covered by the claims.
• Patent strength depends on the novelty, inventive step, and claim breadth relative to prior art.

Key Takeaways

• DK2237799 grants protection for a specific pharmaceutical composition or method within Denmark.
• Its scope hinges on detailed claims defining composition, dosage, and use.
• It is part of a wider patent family aiming for international protection.
• The patent's strength and enforceability depend on claims' novelty over prior art.
• The commercial viability depends on patent term, market relevance, and potential for licensing or litigation.

FAQs

1. What active ingredients are covered by DK2237799?
   The specific active ingredient(s) are detailed in the claims; likely a novel compound or combination.

2. Can DK2237799 be challenged based on prior art?
   Yes, if prior art discloses similar compositions or uses, a validity challenge could succeed.

3. What is the expiry date of DK2237799?
   Approximate expiration is 20 years from filing, around 2030–2035, subject to extensions; actual date depends on the filing year.

4. Is DK2237799 part of a broader patent family?
   Most likely yes, with corresponding filings in other jurisdictions like EP or US, enhancing global patent estate.

5. How does this patent impact the market for its intended therapeutic area?
   It provides exclusivity, potentially delaying generic entry, and influencing licensing or collaboration opportunities.

---

References

1. European Patent Office. (2023). Patent law overview. https://www.epo.org
2. World Intellectual Property Organization. (2023). Patent family and coverage. https://www.wipo.int
3. Danish Patent Office. (2023). Patent procedure and regulations. https://www.dkpto.dk